Last quarter (Q2 2022), OSE Immunotherapeutics SA's total revenue was €―, a decrease of ― from the same quarter last year. In Q2, OSE Immunotherapeutics SA's net income was €―. See OSE Immunotherapeutics SA’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18	Dec 17
Total Revenue	-	€ 26.31M	€ 10.42M	€ 25.95M	€ 24.46M	€ 6.68M
Cost of Revenue	-	-	-	€ 8.00K	€ 4.00K	-
Gross Profit	-	-	-	€ 25.94M	€ 24.45M	-
Operating Expense	-	€ 42.93M	€ 29.41M	€ 27.42M	€ 19.61M	€ 19.31M
Operating Income	-	€ -16.63M	€ -18.99M	€ -1.47M	€ 4.85M	€ -12.63M
Net Non Operating Interest Income Expense	-	€ -829.00K	€ -261.00K	€ -109.00K	€ -150.00K	€ -26.00K
Other Income Expense	-	-	-	-	-	-
Pretax Income	-	€ -17.21M	€ -19.25M	€ -1.46M	€ 4.71M	€ -12.74M
Tax Provision	-	€ -364.00K	€ -2.69M	€ 3.19M	€ -783.00K	€ -2.24M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	€ -16.85M	€ -16.55M	€ -4.65M	€ 5.49M	€ -10.50M
Basic EPS	-	€ -0.93	€ -1.06	€ -0.31	-	-
Diluted EPS	-	€ -0.93	€ -1.06	€ -0.31	-	-
Basic Average Shares	-	€ 18.15M	€ 15.56M	€ 14.89M	-	-
Diluted Average Shares	-	€ 18.15M	€ 15.56M	€ 14.89M	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	€ 42.93M	€ 29.41M	€ 27.42M	€ 19.61M	€ 19.31M
Net Income From Continuing And Discontinued Operation	-	€ -16.85M	€ -16.55M	€ -4.65M	€ 5.49M	€ -10.50M
Normalized Income	-	€ -17.05M	€ -16.55M	€ -4.70M	€ 5.50M	€ -10.50M
Interest Expense	-	€ 836.00K	€ 273.00K	€ 181.00K	€ 186.00K	€ 77.00K
EBIT	-	€ -16.38M	€ -18.97M	€ -1.28M	€ 4.89M	€ -12.66M
EBITDA	-	€ -13.72M	€ -18.24M	€ -801.00K	€ 5.01M	€ -12.54M

Currency in EUR

OSE Immunotherapeutics SA Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing